Hemogenyx Pharmaceuticals plc
(the “Company”)
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company’s Financial Controller and Company Secretary (PDMR), and his wife, Olena Wright, have purchased a total of 434,704 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at an average price of 5.76p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,532,109 Ordinary Shares, representing approximately 0.35 per cent of the Company’s issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1. | Details of PDMR/person closely associated with them | |||||
| a) | Name | Andrew Wright | ||||
| b) | Position/status | PDMR: Financial Controller and Company Secretary | ||||
| c) | Initial notification/ amendment |
Initial notification | ||||
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument | Ordinary shares of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24 |
||||
| b) | Nature of the transaction | Standalone acquisition of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information – Aggregated volume – Price |
|
||||
| e) | Date of the transaction | 2020-06-29 | ||||
| f) | Place of the transaction | London Stock Exchange XLON |
||||
| 1. | Details of PDMR/person closely associated with them | |||||
| a) | Name | Olena Wright | ||||
| b) | Position/status | PCA: Spouse of Andrew Wright (PDMR: Financial Controller and Company Secretary) | ||||
| c) | Initial notification/ amendment |
Initial notification | ||||
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument | Ordinary shares of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24 |
||||
| b) | Nature of the transaction | Standalone acquisition of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information – Aggregated volume – Price |
|
||||
| e) | Date of the transaction | 2020-06-29 | ||||
| f) | Place of the transaction | London Stock Exchange XLON |
||||
Enquiries:
| Hemogenyx Pharmaceuticals plc | hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
| Peter Redmond, Director | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Soltan Tagiev | |
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey | |
| US Media enquiries | Tel: +1 (323) 646-3249 |
| Lowell Goodman | lowell@corbomitecomms.com |